ENTERA BIO LTD. (ENTX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -14.40M USD | Operating Income (Loss) |
| Revenue | 0.00 USD | |
| Cost of products and services | (m) | |
| Research and development | 8.81M USD | Research and Development Expense |
| Selling, general and administration | 424.00K USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-14.40M | $0.00 | (m) | $8.81M | $424.00K | (m) |
| 2026-03-31 | $-12.51M | $0.00 | (m) | $7.13M | $403.00K | (m) |
| 2025-12-31 | $-11.53M | $42.00K | (m) | $6.00M | $398.00K | -27450.00% |
| 2025-09-30 | $-10.82M | $124.00K | (m) | $5.49M | (m) | -8729.03% |
| 2025-06-30 | $-10.59M | $166.00K | (m) | $5.32M | (m) | -6378.92% |
| 2025-03-31 | $-10.09M | $223.00K | (m) | $4.89M | (m) | -4522.87% |
| 2024-12-31 | $-9.59M | $181.00K | (m) | $4.50M | (m) | -5295.58% |
| 2024-09-30 | $-9.21M | $99.00K | (m) | $4.30M | (m) | -9304.04% |
| 2024-06-30 | $-8.58M | $57.00K | (m) | $4.19M | (m) | -15045.61% |
| 2024-03-31 | $-8.74M | (m) | (m) | $4.31M | (m) | (m) |
| 2023-12-31 | $-8.89M | $0.00 | (m) | $4.51M | (m) | (m) |
| 2023-09-30 | $-10.00M | $14.00K | (m) | $4.86M | (m) | -71400.00% |
| 2023-06-30 | $-10.47M | $22.00K | (m) | $4.90M | (m) | -47613.64% |
| 2023-03-31 | $-11.39M | $66.00K | (m) | $5.09M | (m) | -17263.64% |
| 2022-12-31 | $-13.02M | $134.00K | (m) | $5.85M | (m) | -9714.18% |
| 2022-09-30 | $-14.04M | $285.00K | (m) | $7.15M | (m) | -4925.26% |
| 2022-06-30 | $-14.39M | $417.00K | (m) | $7.50M | (m) | -3451.32% |
| 2022-03-31 | $-13.71M | $482.00K | (m) | $7.34M | (m) | -2845.02% |
| 2021-12-31 | $-12.22M | $571.00K | (m) | $6.77M | (m) | -2139.58% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-11.17M | $365.00K | (m) | $6.38M | (m) | -3059.73% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |